ReviewBiomedicines2021
Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Corticosteroid-resistant immune-related adverse events: a systematic review.Journal for immunotherapy of cancer · 2024Pooled it
- From inflammatory phenotypes to clinical decisions: a stratified diagnostic and therapeutic framework for CIP.Frontiers in immunology · 2026Review
- Interactions between interstitial lung abnormalities and immune checkpoint inhibitor therapy in non-small cell lung cancer: A review of current understanding and future directions.Human vaccines & immunotherapeutics · 2025Review
- Immune Checkpoint Inhibitor-Induced Insidiously Progressive, Fatal Interstitial Lung Disease.Journal of personalized medicine · 2025Article
- Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Acute respiratory distress syndrome (ARDS): from mechanistic insights to therapeutic strategies.MedComm · 2025Review
- Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis.Frontiers in immunology · 2025Review
- Efficacy and safety of thoracic radiotherapy combined with anti-angiogenic therapy and immunochemotherapy for advanced non-small cell lung cancer patients: a retrospective study.Frontiers in oncology · 2025Article
- Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).Experimental and therapeutic medicine · 2024Review
- The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.Scientific reports · 2024Article
- Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.eLife · 2024Article
- Pulmonary toxicity of immune checkpoint immunotherapy.The Journal of clinical investigation · 2024Review
- Lung Transplantation for Pleuroparenchymal Fibroelastosis: A Single-Center Experience with Revision of Literature.Biomedicines · 2023Article
- Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings.La Radiologia medica · 2023Article
- Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report.JTO clinical and research reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death-1 (PD-1), and programmed cell death-1-ligand 1 (PD-L1) have become new treatment options for various malignancies. ICIs bind to immune-checkpoint inhibitory receptors or to the foregoing ligands and block inhibitory signals to release the brakes on the immune system, thereby enhancing immune anti-tumor responses. On the other hand, unlike conventional chemotherapies, ICIs can cause specific side effects, called immune-related adverse events (irAEs). These toxicities may affect various organs, including the lungs. ICI-related pneumonitis (ICI-pneumonitis) is not the most frequent adverse event, but it is serious and can be fatal. In this review, we summarize recent findings regarding ICI-pneumonitis, with a focus on potential pathogenesis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.